New updates have been reported about Function Health.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Function Health has acquired SuppCo, an independent supplement intelligence platform, in a move to integrate real-time biological testing with evidence-based guidance on what people put into their bodies. The deal extends Function’s model beyond labs, MRI, and CT into an “action layer” that links members’ biomarker data with personalized, independently validated supplement regimens, addressing a major trust and safety gap in a category used by more than half of Americans.
By combining Function’s longitudinal testing infrastructure with SuppCo’s app, TrustScore rating system, and analysis of over 35,000 products and 500,000 supplement routines, the company aims to create a closed loop: measure biology, map the inputs acting on it, and adjust interventions based on outcomes. SuppCo’s ISO 17025–based TESTED program, which has already shown that roughly half of leading supplements fail label accuracy checks, will be folded into Function’s platform to support clinically guided, brand-agnostic recommendations that are not tied to supplement sales economics.
Function positions this acquisition as a critical step in building its AI health operating system, enabling members to see lab trends, imaging results, and supplement effects in one integrated interface. CEO and co-founder Jonathan Swerdlin said the combined platform is designed to strip away marketing noise and make health decisions simpler by grounding them in individualized data, while SuppCo founder Steve Martocci emphasized that access to Function’s broader biological signals completes the efficacy loop for supplementation.
The transaction also brings in experienced venture-backed infrastructure, as SuppCo counts investors such as Greylock, Union Square Ventures, True Ventures, BoxGroup, and Compound, potentially deepening Function’s capital and partnership network. Strategically, the move differentiates Function from traditional diagnostics providers by pairing its Medical Intelligence Lab’s research capabilities with a scalable, consumer-facing tool that can drive behavior change and long-term engagement.
Function, which offers more than 160 lab tests and optional MRI and CT scans augmented by FDA-cleared AI across the U.S. and U.K., expects the combined offering to increase member lifetime value and create new monetization channels around personalized health protocols. For executives and investors, the acquisition signals Function’s intent to evolve from a diagnostics subscription service into an end-to-end health operating layer that manages both the observation of biology and the interventions that shape it, with implications for future partnerships in food, prescriptions, and broader preventive care.
If successfully executed, the integration with SuppCo could enhance Function’s data moat by capturing detailed information on supplement usage patterns alongside longitudinal lab and imaging results, strengthening its AI models and clinical insights. This, in turn, may improve retention, support payer or employer discussions, and position Function as a leading independent arbiter of supplement quality and health impact at a time when regulatory oversight and consumer skepticism remain high.
Function’s leadership frames the acquisition as a foundation for closing the gap between health data and practical, day-to-day decisions, aiming to make preventive, data-driven care accessible at scale. The company will continue to operate across all 50 states, with SuppCo’s tools embedded into the member experience to support more precise, adaptive supplement strategies aligned with evolving research and individual goals.
In the near term, Function plans to integrate SuppCo’s trust infrastructure into its clinician-guided protocols, allowing providers to recommend supplements backed by both third-party testing and real-world outcomes from the combined user base. Over time, the firm is likely to explore expanded testing, broader categories of inputs, and additional AI-driven insights as it pursues its ambition to help members live 100 healthy years.

